Potential New Trend-Setting Lifecycle Management Enabled by Personalized Medicine - Diaceutics
+

Potential New Trend-Setting Lifecycle Management Enabled by Personalized Medicine

July 16th, 2013

Patrick Considine

Patrick Considine of Diaceutics comments on the recent approvals of Tarceva® and Gilotrif™, highlighting that the approval of Tarceva® for Roche is an interesting and potentially trend-setting new lifecycle management  approach. 

In May and July of 2013, respectively, the FDA approved two targeted therapies for non-small cell lung cancer, Tarceva® (erlotinib, Roche) and Gilotrif™ (afatinib, Boehringer Ingelheim). In both cases, they were concurrently approved with a proprietary companion diagnostic test (CDx) that detects EGFR exon 19 deletions or exon 21 L858R substitution gene mutations. 

http://www.cancernetwork.com/lung-cancer/content/article/10165/2142929

https://www.diaceutics.com/arup-laboratories-and-labceutics-form-strategic-alliance-to-better-serve-personalized-healthcare-market/

It is noteworthy that in both cases the use of CDx tests identified metastatic NSCLC sub-populations that best responded to the therapies and enabled FDA approvals for first-line treatment. In the case of Gilotrif™, such a first-line indication was indeed achieved at its first approval, a remarkable achievement in NSCLC. In contrast, Tarceva® received its original FDA approval in 2004 for use in a broad, untargeted NSCLC population and “after failure of at least one prior chemotherapy regimen” only. Its recent new approval for first-line use in EGFR mutation-positive patients illustrates an interesting and potentially trend-setting new lifecycle management  approach by Roche.

Blogs

View all blogs

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications